Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy

Authors

G AA Burke
A Beishuizen
D Bhojwani
B Burkhardt
V Minard-Colin
R Norris
E Kabickova
F G. Pinarli
N Tacyildiz
J de Jong
G Liu
A Howes
K Nottage
M Salman
X W. de Trixe
Mitchell Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

6-2019

DOI

10.1002/hon.27_2629

Journal Title

Hematalogical Oncology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Disciplines

Medicine and Health Sciences

Recommended Citation

Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R., Kabickova, E., Pinarli, F. G., Tacyildiz, N., de Jong, J., Liu, G., Howes, A., Nottage, K., Salman, M., de Trixe, X. W., & Cairo, M. (2019). Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy. Hematalogical Oncology, 37 (52 Suppl.), 57-59. https://doi.org/10.1002/hon.27_2629